Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. The company has a strong ...

Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 26, Merck & Co., Inc.

Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory ...

Elanco Animal Health said on Wednesday the U.S. Department of Agriculture (USDA) has approved its canine flu vaccine, which ...

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.

Merck’s Enflonsia is part of the company’s growing vaccine portfolio, which has become an increasingly important revenue segment alongside its oncology and other pharmaceutical divisions.

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s Enflonsia.

About ENFLONSIA™ (clesrovimab-cfor) ENFLONSIA is Merck’s extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of ...

ACIP recommends use of Merck’s Enflonsia™ (clesrovimab-cfor) for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants younger than 8 months of age born ...